ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) Plus Androgen-Deprivation Therapy (ADT) in Patients (pts) With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Andrew J. Armstrong, MD, ScM, FACP, presented 5-year follow-up data from the ARCHES trial showing that enzalutamide plus androgen-deprivation therapy significantly prolonged overall survival versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer, with consistent benefit across subgroups and no new safety signals.

Related Content:

Rapid Readouts

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study

Lurbinectedin + Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Results of the Phase 3 IMforte Trial

A First-in-Human, Phase 1a/b, Dose-Escalation/Expansion Study of BG-68501, a Selective CDK2 Inhibitor, as Monotherapy or in Combination With Fulvestrant for Patients With HR+/HER2– Breast Cancer and Other Advanced Solid Tumors: First Disclosure of Clinical Data